Xilio Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -96.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $8.96 | $13.37 | $7.70 | $37.66 | $224.00 | |
| P/S | — | 1.2x | 7.8x | — | — | — |
| P/B | 1.5x | 1.5x | 2.8x | 0.5x | 0.7x | 2.4x |
| EPS | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INKTMiNK Therapeutics, Inc. | $11.43 | — | — | — | — | $58.32M |
| SRTSSensus Healthcare, Inc. | $3.52 | — | 1.6x | — | -34.83% | $57.95M |
| IMAImageneBio, Inc. | $5.34 | — | 0.4x | — | -82.68% | $60.74M |
| HYPDHyperion Defi Inc | $3.92 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Company description provided by Yahoo Finance.
| Profit margin | — | -80.05% | -918.05% | — | — | — |
| ROE | -99.33% | -99.33% | -330.95% | -207.47% | -83.51% | -40.88% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.6x |
| — |
| 9.55% |
| $60.84M |
| TLPHTalphera Inc | $1.20 | — | 3.3x | — | -143.36% | $62.29M |
| IMMPIMMUTEP Ltd | $0.38 | — | 0.8x | — | -61.85% | $56.15M |